Results 1 to 10 of about 134,017 (204)

Scientific Opinion on the safety evaluation of the active substance iron (II) modified bentonite as oxygen absorber for use in active food contact materials [PDF]

open access: yesEFSA Journal, 2012
<p>This scientific opinion of EFSA deals with the safety evaluation of the active substance iron (II) modified bentonite (FCM Substance No 1003) intended to be incorporated in monolayer or multilayer packages or in sachets for absorbing oxygen from
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF)
doaj   +3 more sources

Targeted review of maximum residue levels (MRLs) for fenarimol

open access: yesEFSA Journal, 2023
In accordance with Article 43 of Regulation (EC) 396/2005, EFSA received a request from the European Commission to review the existing maximum residue levels (MRLs) for the non‐approved active substance fenarimol in view of the possible lowering of the ...
European Food Safety Authority (EFSA)   +30 more
doaj   +1 more source

Targeted review of maximum residue levels (MRLs) for bifenthrin

open access: yesEFSA Journal, 2023
In accordance with Article 43 of Regulation (EC) 396/2005, EFSA received a request from the European Commission to review the existing maximum residue levels (MRLs) for the non‐approved active substance bifenthrin in view of the possible lowering of the ...
European Food Safety Authority (EFSA)   +32 more
doaj   +1 more source

Targeted review of maximum residue levels (MRLs) for diazinon

open access: yesEFSA Journal, 2023
In accordance with Article 43 of Regulation (EC) 396/2005, EFSA received a request from the European Commission to review the existing maximum residue levels (MRLs) for the non‐approved active substance diazinon in view of the possible lowering of the ...
European Food Safety Authority (EFSA)   +32 more
doaj   +1 more source

Targeted review of maximum residue levels (MRLs) for chlorfenapyr

open access: yesEFSA Journal, 2023
In accordance with Article 43 of Regulation (EC) 396/2005, EFSA received a request from the European Commission to review the existing maximum residue levels (MRLs) for the non‐approved active substance chlorfenapyr in view of the possible lowering of ...
European Food Safety Authority (EFSA)   +32 more
doaj   +1 more source

Targeted review of maximum residue levels (MRLs) for fenpropathrin

open access: yesEFSA Journal, 2023
In accordance with Article 43 of Regulation (EC) 396/2005, EFSA received a request from the European Commission to review the existing maximum residue levels (MRLs) for the non‐approved active substance fenpropathrin in view of the possible lowering of ...
European Food Safety Authority (EFSA)   +31 more
doaj   +1 more source

Targeted review of maximum residue levels (MRLs) for endosulfan

open access: yesEFSA Journal, 2023
In accordance with Article 43 of Regulation (EC) 396/2005, EFSA received a request from the European Commission to review the existing maximum residue levels (MRLs) for the non‐approved active substance endosulfan in view of the possible lowering of the ...
European Food Safety Authority (EFSA)   +30 more
doaj   +1 more source

Targeted review of maximum residue levels (MRLs) for dicofol

open access: yesEFSA Journal, 2023
In accordance with Article 43 of Regulation (EC) 396/2005, EFSA received a request from the European Commission to review the existing maximum residue levels (MRLs) for the non‐approved active substance dicofol in view of the possible lowering of the MRL.
European Food Safety Authority (EFSA)   +32 more
doaj   +1 more source

Targeted review of maximum residue levels (MRLs) for profenofos

open access: yesEFSA Journal, 2023
In accordance with Article 43 of Regulation (EC) 396/2005, EFSA received a request from the European Commission to review the existing maximum residue levels (MRLs) for the non‐approved active substance profenofos in view of the possible lowering of the ...
European Food Safety Authority (EFSA)   +32 more
doaj   +1 more source

Lifecycle management of orphan drugs approved in Japan

open access: yesOrphanet Journal of Rare Diseases, 2022
Background The development of orphan drugs (ODs) is challenging from both development and business perspectives because of their small patient populations.
Kiyoshi Seki   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy